Tumor Biology

, Volume 32, Issue 2, pp 259–264 | Cite as

MMP-7 as a prognostic marker in colorectal cancer

  • Selja Koskensalo
  • Johanna Louhimo
  • Stig Nordling
  • Jaana Hagström
  • Caj Haglund
Research Article


Matrix metalloproteinase-7 is capable of degrading many extracellular matrix proteins and cellular adhesions. In many malignancies, it is overexpressed, and it plays a role in cancer progression by enhancing tumor invasion and thereby metastatic potential. The purpose of this study was to evaluate the association between MMP-7 tissue expression and prognosis in colorectal cancer. From 623 patients who underwent surgery for colorectal cancer, surgical specimens were collected into tissue array blocks and stained by immunohistochemistry for MMP-7. Specimens from 545 patients were suitable for analysis. In specimens from 105 patients (19.3%), MMP-7 scored as high; in 103 (18.9%), as moderate; and in 134 (24.9%), as mild. In 203 cases (37.2%), immunoreactivity was negative. A significant correlation appeared between MMP-7 immunoexpression and tumor differentiation. High MMP-7 positivity associated with poor prognosis during a 5-year follow-up. During longer follow-up, the differences in survival between groups disappeared. MMP-7 is a potential target for tumor therapy, which should be evaluated in clinical trials.


MMP-7 Colorectal cancer Immunohistochemistry Prognosis 



We thank Päivi Peltokangas, Tuire Koski, and Elina Aspiala for technical assistance.


This study was supported by Finska Läkaresällskapet, Medicinska Understödsföreningen Liv och Hälsa, and the Sigrid Jusélius Foundation.

Ethics approval

The study has been approved by local ethics committee and complies with the Declaration of Helsinki (Dnro HUS 226/E6/06).


  1. 1.
    Globocan 2002 Database.Google Scholar
  2. 2.
    Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23:101–17.CrossRefPubMedGoogle Scholar
  3. 3.
    Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996;3:895–904.CrossRefPubMedGoogle Scholar
  4. 4.
    MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Can Met Rev. 1995;14:351–62.CrossRefGoogle Scholar
  5. 5.
    Powell WC, Matrisian LM. Complex roles of matrix metalloproteinases in tumor progression. Curr Top Microbiol Immunol. 1996;213:1–21.PubMedGoogle Scholar
  6. 6.
    Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–85.CrossRefPubMedGoogle Scholar
  7. 7.
    Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis. 2006;27:1113–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Von Bredow DC, Nagle RB, Bowden GT, Cress AE. Cleavage of beta 4 integrin by matrilysin. Exp Cell Res. 1997;236:341–5.CrossRefGoogle Scholar
  9. 9.
    Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med. 2006;231:20–7.Google Scholar
  10. 10.
    Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut. 1999;45:252–8.CrossRefPubMedGoogle Scholar
  11. 11.
    McDonnell S, Navre M, Coffey RJ Jr, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4:527–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Adachi Y, Itoh F, Yamamoto H, Matsuno K, Arimura Y, Kusano M, et al. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. Int J Oncol. 1998;13:1931–5.Google Scholar
  13. 13.
    Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest. 2002;109:1437–44.PubMedGoogle Scholar
  14. 14.
    Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol. 2001;19:1118–27.PubMedGoogle Scholar
  15. 15.
    Pjouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol. 1991;117:144–50.CrossRefGoogle Scholar
  16. 16.
    Muller D, Breatchnach R, Engelmann A, Millon R, Bronner G, Flesch H, et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer. 1991;48:550–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990;348:699–704.CrossRefPubMedGoogle Scholar
  18. 18.
    Yamamoto H, Itoh F, Adachi Y, Sakamoto H, Adachi M, Hinoda Y, et al. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology. 1997;112:1290–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagström J, et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010;31:149–55.CrossRefPubMedGoogle Scholar
  20. 20.
    Davis NC, Evans EB, Cohen JR, Theile DE. Staging of colorectal cancer. The Australian clinico-pathological staging (ACPS) system compared with Dukes’ system. Dis Colon Rectum. 1984;27:707–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer. 1998;79:187–94.CrossRefPubMedGoogle Scholar
  22. 22.
    Railo M, Lundin J, Haglund C, von Smitten C, Nordling S. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumor Biol. 2007;28:45–51.CrossRefGoogle Scholar
  23. 23.
    Hilsenbeck SG, Ravdin PM, deMoor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998;52:227–37.CrossRefPubMedGoogle Scholar
  24. 24.
    Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. STn and prognosis in breast cancer. Oncology. 2001;61:299–305.CrossRefPubMedGoogle Scholar
  25. 25.
    Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat. 2001;67:15–22.CrossRefPubMedGoogle Scholar
  26. 26.
    Engellau J. Prognostic factors in soft tissue sarcoma. Tissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence. Acta Orthop Scand Suppl. 2004;314:1–52.Google Scholar
  27. 27.
    Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog. 1994;10:199–206.CrossRefPubMedGoogle Scholar
  28. 28.
    Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene. 2003;22:8662–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer. 2001;84:1317–21.CrossRefPubMedGoogle Scholar
  30. 30.
    Ishikawa T, Ichikawa Y, Mitsuhashi M, Momiyama N, Chishima T, Tanaka K, et al. Matrilysin is associated with progression of colorectal tumor. Cancer Lett. 1996;1(107):5–10.CrossRefGoogle Scholar
  31. 31.
    Tokoro T, Okuno K, Hida J, Ishimaru E, Ueda K, Yoshifuji T. Depth of mesorectal invasion has prognostic significance in T3N0 low rectal cancer. Hepatogastroenterology. 2009;56:124–7.PubMedGoogle Scholar
  32. 32.
    Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115:3379–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Mimori K, Yamashita K, Ohta M, Yoshinaga K, Ishikawa K, Ishii H, et al. Coexpression of matrix metalloproteinase (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells. Clin Cancer Res. 2004;10:8243–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Selja Koskensalo
    • 1
  • Johanna Louhimo
    • 1
  • Stig Nordling
    • 2
  • Jaana Hagström
    • 2
  • Caj Haglund
    • 1
    • 2
  1. 1.Department of SurgeryHelsinki University Central HospitalHelsinkiFinland
  2. 2.Department of PathologyHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations